Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Rhea-AI Summary

Propanc Biopharma (NASDAQ: PPCB), a biopharmaceutical company focused on novel cancer treatments, has successfully completed its public offering and uplisting to the Nasdaq Capital Market. The company sold 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 Million.

Trading under the symbol "PPCB" commenced on August 15, 2025, with the offering closing on August 18, 2025. The underwriters, D. Boral Capital LLC and Craft Capital Management LLC, have a 45-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts.

Positive

• Successfully uplisted to Nasdaq Capital Market, providing increased visibility and potential liquidity
• Raised $4 Million in gross proceeds through public offering
• Additional potential capital through 45-day underwriter option for 150,000 shares

Negative

• Dilution of existing shareholders through new share issuance
• Offering-related expenses will reduce net proceeds available to company

Insights

Healthcare Financial Analyst

Propanc Biopharma raised $4M through NASDAQ uplisting, significantly enhancing visibility and capital access for its cancer treatment development.

Propanc Biopharma has successfully completed a $4 million public offering coinciding with its uplisting to the NASDAQ Capital Market. The company sold 1,000,000 shares at $4.00 per share, with trading commencing on August 15 under the ticker symbol "PPCB". Additionally, underwriters received a 45-day option to purchase up to 150,000 additional shares at the same price.

This uplisting represents a significant milestone for the oncology-focused biopharmaceutical company. Moving from the over-the-counter market to NASDAQ provides substantially increased visibility, liquidity, and access to institutional investors who often have restrictions preventing investments in non-listed securities. The $4 million capital injection, while modest compared to typical biotech raises, provides critical funding for Propanc's novel cancer treatments targeting recurring and metastatic cancer.

The successful offering was managed by D. Boral Capital LLC and Craft Capital Management LLC as book-running managers. While the gross proceeds amount to $4 million, the net proceeds will be lower after accounting for underwriting discounts and related expenses. The capital raise strengthens Propanc's financial position as it advances its cancer treatment pipeline, though specific allocation of funds wasn't detailed in this announcement.

For a development-stage biopharmaceutical company, this NASDAQ uplisting creates a potential pathway to additional capital raises with improved terms, greater analyst coverage, and enhanced corporate credibility within the investment community and pharmaceutical industry. These advantages could prove valuable as Propanc continues developing treatments for patients with recurring and metastatic cancer.

MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that it closed an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The shares of common stock commenced trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol, “PPCB”.

The Company received aggregate gross proceeds of $4 Million from the offering, before deducting underwriting discounts and other related expenses. In addition, the Company has also granted the underwriter a 45-day option to purchase up to 150,000 additional shares of common stock at the public offering price, less underwriting discounts. The closing for the initial public offering occurred on August 18, 2025.

D. Boral Capital LLC and Craft Capital Management LLC acted as the book running managers for the offering.

Brunson Chandler & Jones PLLC, Salt Lake City, Utah, acted as counsel to the Company, and Sichenzia Ross Ference Carmel LLP, New York, NY, acted as counsel to the underwriters in connection with the offering.

A registration statement on Form S-1 relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 13, 2025. The proposed offering was made by means of a prospectus. Electronic copies of the prospectus will also be available on the SEC’s website at http://www.sec.gov or from D Boral Capital LLC, Attention: 590 Madison Avenue 39^th Floor, New York, NY 10022, or by email at info@dboralcapital.com, or by telephone at +1(212)-970-5150.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.

The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com

FAQ

When did Propanc Biopharma (PPCB) uplist to NASDAQ?

Propanc Biopharma began trading on the Nasdaq Capital Market on August 15, 2025 under the symbol PPCB.

How much money did Propanc Biopharma raise in its public offering?

Propanc Biopharma raised $4 Million in gross proceeds through the sale of 1,000,000 shares at $4.00 per share.

What was the share price for Propanc Biopharma's public offering?

The public offering price was $4.00 per share for common stock.

Who were the underwriters for Propanc Biopharma's NASDAQ uplisting?

D. Boral Capital LLC and Craft Capital Management LLC acted as the book running managers for the offering.

What is the underwriter option in Propanc Biopharma's public offering?

The underwriters have a 45-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts.